РОЛЬ ГИПЕРУРИКЕМИИ В ПРОГРЕССИРОВАНИИ И ПАТОГЕНЕЗЕ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
Аннотация
В данной статье рассматриваются взаимосвязь мочевой кислоты с основными компонентами метаболического синдрома и факторами, влияющими на патогенез НАЖБП. Доказано, что гиперурикемия может являться независимым фактором, вносящим свой вклад в развитие и прогрессирование НАЖБП. Применение игибитора ксантиноксидазы – фебуксостата – в экспериментальных исследованиях показало значимый протекторный эффект при НАЖБП.
Литература
1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231. doi: 10.1056/ NEJMra011775.
2. Kim D, Chung GE, Kwak MS, Seo HB, Kang JH, Kim W, Kim YJ, Yoon JH, Lee HS, Kim CY. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):132-138:e4. doi: 10.1016/j.cgh.2015.07.024.
3. Wattacheril J, Sanyal AJ. Lean NAFLD: an underrecognized outlier. Curr Hepatology Rep. 2016;15(2):134-139. doi: 10.1007/s11901-016-0302-1.
4. Chan WK, Nik Mustapha NR, Wong GL, Wong VW, Mahadeva S. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol Journal. 2016;5(1):76-85. doi: 10.1177/2050640616646528.
5. Clark JM, Brancati FL, Diehl AM. The prevalense and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-967. doi: 10.1111/j.1572-0241.2003.07486.x.
6. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A metaanalysis of diagnostic accuracy. J. Hepatol. 2011;54(4):650-659. doi: 10.1016/j.jhep.2010.07.033.
7. Mount DB, Kwon CY, Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am. 2006;32(2):313-331. doi: 10.1016/j.rdc.2006.02.006.
8. Nomura J, Busso N, Ives A, Tsujimoto S, Tamura M, So A, Yamanaka Y. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS One. 2013;25(8):e75527. doi: 10.1371/journal.pone.0075527.
9. Sertoglu E, Ercin CN, Celebi G, Gurel H, Kayadibi H, Genc H, Kara M, Dogru T. The relationship of serum uric acid with nonalcoholic fatty liver disease. Clin Biochem. 2014;47(6):383-388. doi: 10.1016/j.clinbiochem.2014.01.029.
10. Lonardo A, Loria P, Leonardi F, Pulvirenti M, Verrone AM, Ganazzi D, Carulli N. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig. Liver Dis. 2002;34(3):204-211.
11. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: A crosssectional study. J Hepatol. 2009;50(5):1029-1034. doi: 10.1016/j.jhep.2008.11.021.
12. Ryu S, Chang Y, Kim SG, Cho J, Guallar E. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism. 2011;60(6):860-866. doi: 10.1016/j.metabol.2010.08.005.
13. Liu Z, Que S, Zhou L, Zheng S. Dose-response relationship of serum uric acid with metabolic syndrome and nonalcoholic fatty liver disease incidence: A meta-analysis of prospective studies. Sci Rep. 2015;23(5):Art.14325. doi: 10.1038/srep14325.
14. Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, Zhang Z, Yang Z. Serum uric acid levels and risk of metabolic syndrome: A dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2015;100(11):4198-4207. doi: 10.1210/jc.2015-2527.
15. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: A Chinese cohort study. Arthritis Rheum. 2009;61(2):225-232. doi: 10.1002/art.24164.
16. Gong S, Song J, Wang L, Zhang S, Wang Y. Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2016;28(2):132-138. doi: 10.1097/MEG.0000000000000507.
17. Huang F, Liu A, Fang H, Geng X. Serum uric acid levels in non-alcoholic steatosis patients: a meta-analysis. Asia Pac J Clin Nutr. 2017;26(2):334-342. doi: 10.6133/apjcn.092016.04.
18. Liu PJ, Ma F, Lou HP, Zhu YN, Chen Y. Relationship between serum uric acid levels and hepatic steatosis in nonobese postmenopausal women. Climacteric. 2014;17(6):692-699. doi: 10.3109/13697137.2014.926323.
19. Wijarnpreecha K, Panjawatanan P, Lekuthai N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. Liver Int. 2017;37(6):906-918. doi: 10.1111/liv.13329.
20. Xu C, Wan X, Xu L, Weng H, Yan M, Miao M, Sun Y, Xu G, Dooley S, Li Y, Li С. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. J Hepatol. 2015;62(6):1412-1419. doi: 10.1016/j.jhep.2015.01.019.
21. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013;62(3):392-399. doi: 10.1016/j.metabol.2012.08.013.
22. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(7):757-766. doi: 10.1111/j.1365-2036.2011.04788.x.
23. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Сha BS. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164(19):2169-2175. doi: 10.1001/archinte.164.19.2169.
24. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J. Gastroenterol. Hepatol. 2012;27(10):1555-1560. doi: 10.1111/j.1440-1746.2012.07222.
25. Oral A, Sahin T, Turker F, Kocak E. Relationship between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients. Medicina. 2019;55(9):600. doi: 10.3390/medicina55090600.
26. Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology. 2010;52(2):578-589. doi: 10.1002/hep.23717.
27. Abreu E, Fonseca MJ, Santos AC. Association between hyperuricemia and insulin resistance. Acta Med. Port. 2011;24(Suppl 2):565-574.
28. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737-1742. doi: 10.2337/dc09-0288.
29. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Sautin YY, Johnson RJ. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287(48):40732-40744. doi: 10.1074/jbc.M112.399899.
30. Pagliassotti MJ. Endoplasmic reticulum stress in nonalcoholic fatty liver disease. Annu Rev Nutr. 2012;32:17-33. doi: 10.1146/annurev-nutr-071811-150644.
31. Zhang C, Chen X, Zhu RM, Zhang Y, Yu T, Wang H, Zhao H, Zhao M, Ji YL, Chen YH, Meng XH, Wei W, Xu DX. Endoplasmic reticulum stress is involved in hepatic SREBP-1c activation and lipid accumulation in fructosefed mice. Toxicol Lett. 2012;212(3):229-240. doi: 10.1016/j.toxlet.2012.06.002.
32. Choi YJ, Shin HS, Choi HS, Park JW, Jo I, Oh ES, Lee KY, Lee BH, Johnson RJ, Kang DH. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94(10):1114-1125. doi: 10.1038/labinvest.2014.98.
33. Tan Y, Liu X, Zhou K, He X, Lu C, He B, Niu X, Xiao C, Xu G, Bian Z, Zu X, Zhang G, Zhang W, Lu A. The potential biomarkers to identify the development of steatosis in hyperuricemia. PLoS ONE. 2016;11(2):e0149043. doi: 10.1371/journal.pone.0149043.
34. Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A, Mori K, Matsunaga Y, Fukushima T, Kanaoka T, Yamamotoya T, Kamata H, Asano T. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015;309(1):G42-51. doi: 10.1152/ajpgi.00443.2014.
